Nasus Pharma Clears FDA Hurdle for Needle-Free Anaphylaxis Treatment
Event summary
- FDA cleared Nasus Pharma's IND application for NS002, an intranasal epinephrine powder for anaphylaxis treatment.
- Pivotal study planned for Q4 2026 with topline data expected in Q1 2027.
- NS002 achieved 100 pg/mL plasma epinephrine threshold in 1.69 minutes vs. 3.47 minutes for EpiPen in Phase 2 study.
- Company targets $2 billion anaphylaxis treatment market dominated by injectables.
The big picture
Nasus Pharma's FDA clearance positions it to challenge the $2 billion anaphylaxis treatment market currently dominated by needle-based autoinjectors. The company's intranasal epinephrine powder offers a potentially superior alternative with faster onset, addressing a significant unmet need for patients with severe allergies. Success could disrupt the existing market landscape and establish a new standard for anaphylaxis treatment.
What we're watching
- Regulatory Pathway
- Whether FDA will require additional studies before or after the pivotal trial.
- Clinical Timing
- The pace at which the pivotal study progresses and whether it meets the Q1 2027 data readout target.
- Market Disruption
- How NS002's needle-free alternative will compete against established injectable treatments like EpiPen.
Related topics